tiprankstipranks
Advertisement
Advertisement
Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal
PremiumThe FlyWedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal
29d ago
BioCryst price target raised to $14 from $13 at RBC Capital
Premium
The Fly
BioCryst price target raised to $14 from $13 at RBC Capital
29d ago
BioCryst: Strategic Shift to External Rare-Disease Assets and Cost Discipline Supports Unchanged $32 Price Target and Buy Rating
Premium
Ratings
BioCryst: Strategic Shift to External Rare-Disease Assets and Cost Discipline Supports Unchanged $32 Price Target and Buy Rating
1M ago
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
1M ago
BioCryst Shareholders Approve Expanded Equity Incentive Plan
Premium
Company Announcements
BioCryst Shareholders Approve Expanded Equity Incentive Plan
2M ago
BioCryst to present new Orladeyo data at EAACI
Premium
The Fly
BioCryst to present new Orladeyo data at EAACI
2M ago
BioCryst Earnings Call: Growth, Pipeline And New Risks
PremiumCompany AnnouncementsBioCryst Earnings Call: Growth, Pipeline And New Risks
3M ago
BioCryst Buy Rating Reiterated on Orladeyo Strength, Long-Term Growth Potential and Unchanged $30 Price Target
Premium
Ratings
BioCryst Buy Rating Reiterated on Orladeyo Strength, Long-Term Growth Potential and Unchanged $30 Price Target
3M ago
BioCryst Posts Q1 2026 Results, Maintains Growth Outlook
Premium
Company Announcements
BioCryst Posts Q1 2026 Results, Maintains Growth Outlook
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100